Senti Biosciences releases initial Phase 1 clinical data for SENTI-202; no specific results disclosed in filing

Senti Biosciences, Inc.

Initial clinical data from Phase 1 trial of SENTI-202 made available in slide presentation deck.
Data reported under Item 8.01; no specific numeric results or interim analyses provided in the 8-K body.
Company cautions forward-looking statements; risks include clinical trial uncertainties.
Stock ticker SNTI; filing date December 3, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.